A rare presentation of vanishing bile duct syndrome in Hodgkin lymphoma: Case report.

In this report, we present the case of vanishing bile duct syndrome in the setting of classical Hodgkin lymphoma. Vanishing bile duct syndrome was diagnosed retrospectively in this patient with Hodgkin lymphoma, who initially presented with a hepatic abnormality presumed to be drug induced. Vanishing bile duct syndrome is characterized by the disappearance of bile ducts, with the progressive damage resulting in cholestasis.

Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience.

Background: Atezolizumab-bevacizumab (atezo/bev) combination is a recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC). There are no studies from India reporting the safety and efficacy of this drug in real-world settings where most patients present in an advanced stage.

Methods: In this retrospective study from two centers in India, we included patients with uHCC who received atezo/bev as first-line systemic therapy.

CARASIL.

We herewith report a case of 46 year old male with clinical features suggestive of CARASIL (Cerebral Autosomal Recessive Arteriopathy with Sub cortical Infarcts and Leucoencephalopathy). He had recurrent strokes in early age before reaching 35 years. He was normotensive and had severe degenerative changes in lumbar spine and knee joint on radiographs and had diffuse alopecia.